Início › Carcinoma de Células Escamosas de Cabeça e Pescoço › Michigan › Detroit
Ensaios clínicos de Carcinoma de Células Escamosas de Cabeça e Pescoço em Detroit, MI
15 estudos para Carcinoma de Células Escamosas de Cabeça e Pescoço estão buscando participantes em locais em Detroit e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecrutandoFase 1
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecrutandoFase 3
- Karmanos Cancer Institute, Detroit
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RecrutandoFase 1/2
- Karmanos Cancer Institute, Detroit
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecrutandoFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RecrutandoEstudo observacional
- Karmanos Cancer Institute, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecrutandoFase 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RecrutandoFase 2/3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecrutandoFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of DM005 in Patients With Advanced Solid Tumors
RecrutandoFase 1/2
- Henry Ford Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecrutandoFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RecrutandoFase 1
- Karmanos Cancer Institute, Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecrutandoFase 1
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RecrutandoFase 1/2
- Henry Ford Health System, Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecrutandoFase 1/2
- Research Site 129, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RecrutandoFase 1/2
- Karmanos Cancer Institute, Detroit
Ensaios de Carcinoma de Células Escamosas de Cabeça e Pescoço em outras cidades
- Houston, TX47 estudos
- Los Angeles, CA42 estudos
- Boston, MA40 estudos
- New York City, NY39 estudos
- Nashville, TN39 estudos
- St. Louis, MO28 estudos
- Arlington, VA26 estudos
- Philadelphia, PA26 estudos
- Chicago, IL26 estudos
- Atlanta, GA24 estudos
- San Antonio, TX22 estudos
- Pittsburgh, PA22 estudos
Outros estudos em Detroit
- Câncer de Pulmão de Não Pequenas Células44 estudos
- Câncer de Mama33 estudos
- Câncer (todos os tipos)29 estudos
- Câncer Colorretal26 estudos
- Câncer de Ovário26 estudos
- Câncer Metastático24 estudos
- Câncer de Próstata22 estudos
- Câncer Endometrial21 estudos
- Câncer de Pulmão20 estudos
- Mieloma Múltiplo19 estudos
- Câncer de Estômago16 estudos
- Leucemia Mieloide Aguda14 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.